2022 Outlook: MAOs Face Payment-Related Unknowns, Increased Competition

For the Medicare Advantage industry, change wasn’t a major outcome of the Biden administration’s first year in office. But for 2022, MA organizations face a host of unknowns — such as potential risk adjustment and star ratings changes that could impact plan revenue — and challenges that include staying competitive in an increasingly rich benefits landscape. For AIS Health’s annual roundup of perspectives on the year ahead, industry experts weigh in on how doing business in 2022 might differ from previous years.

AIS Health: What do you view as some of the biggest challenges or uncertainties facing MAOs in 2022?

© 2022 MMIT

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/12/WordPress-Featured_AdobeStock_302227179_Editorial_Use_Only.jpg
December 2

Latest OIG Risk Adjustment Audit Seeks $6.4 Million From UPMC

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-medicare-advantage-With-More-Online-Enrollment-MAOs-Must-Add-‘Personal-Touch.jpg
December 2

In AEP Home Stretch, MAOs Make Final Push for Enrollment

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
January 7

2021 Outlook: COVID Will Have Lasting Impact on MAO Investment Targets

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today